Strategies of Viral Vectors for Vaccine Development

Guest Editor:

Dr. Kathleen Hefferon
Department of Cell & Systems Biology, University of Toronto, Toronto, ON M5S 1A1, Canada

Deadline for manuscript submissions:
31 August 2025

Message from the Guest Editor

Dear Colleagues,

Viral vectors have long been explored as potential tools in medicine. As these vectors grow more and more sophisticated, their applications have expanded. Viral vectors can be used to carry drugs, express heterologous proteins, and even target cancer cells. The scope of this Special Issue will include the development of animal, plant and bacterial virus vectors as a means to produce safe, efficacious and inexpensive vaccines. I/We look forward to receiving your contributions.

Special Issue

Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us